Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Pfeuffer

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Journal of Clinical Medicine|October 9, 2019
Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic ReviewLeoni Rolfes, Steffen Pfeuffer, Tobias Ruck, et al.
Frontiers in Immunology|June 20, 2019
Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg CompartmentJürgen Haas, Cornelia Würthwein, Mirjam Korporal-Kuhnke, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 13, 2019
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSFNora Möhn, Steffen Pfeuffer, Tobias Ruck, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 30, 2025
Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosisFranziska Axhausen, Anne Mrochen, Pia Winter, et al.
Multiple Sclerosis and Related Disorders|May 31, 2026
Neuropsychological symptoms and subclinical disease activity in multiple sclerosis patients receiving high-efficacy therapyPauline Mühlenbrock, Pia Winter, Franziska Axhausen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2021
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centresSteffen Pfeuffer, Leoni Rolfes, Jana Hackert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 10, 2019
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MSLeoni Rolfes, Steffen Pfeuffer, Tobias Ruck, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 10, 2021
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine TreatmentLeoni Rolfes, Steffen Pfeuffer, Jana Hackert, et al.
Ebiomedicine|August 3, 2019
Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort studyTobias Ruck, Andreas Schulte-Mecklenbeck, Steffen Pfeuffer, et al.
Multiple Sclerosis and Related Disorders|February 12, 2022
A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumabSaskia Räuber, Marc Pawlitzki, Melanie Korsen, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Journal of Clinical Medicine|October 9, 2019
Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic ReviewLeoni Rolfes, Steffen Pfeuffer, Tobias Ruck, et al.
Frontiers in Immunology|June 20, 2019
Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg CompartmentJürgen Haas, Cornelia Würthwein, Mirjam Korporal-Kuhnke, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 13, 2019
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSFNora Möhn, Steffen Pfeuffer, Tobias Ruck, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 30, 2025
Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosisFranziska Axhausen, Anne Mrochen, Pia Winter, et al.
Multiple Sclerosis and Related Disorders|May 31, 2026
Neuropsychological symptoms and subclinical disease activity in multiple sclerosis patients receiving high-efficacy therapyPauline Mühlenbrock, Pia Winter, Franziska Axhausen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2021
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centresSteffen Pfeuffer, Leoni Rolfes, Jana Hackert, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 10, 2019
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MSLeoni Rolfes, Steffen Pfeuffer, Tobias Ruck, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 10, 2021
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine TreatmentLeoni Rolfes, Steffen Pfeuffer, Jana Hackert, et al.
Ebiomedicine|August 3, 2019
Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort studyTobias Ruck, Andreas Schulte-Mecklenbeck, Steffen Pfeuffer, et al.
Multiple Sclerosis and Related Disorders|February 12, 2022
A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumabSaskia Räuber, Marc Pawlitzki, Melanie Korsen, et al.
Pageof 7